8-K: C4 Therapeutics Reports Q1 2026 Results, Expands Roche Partnership

C4 Therapeutics announced first-quarter 2026 financial results, highlighting progress in its cemsidomide multiple myeloma trials and a new collaboration with Roche focused on degrader-antibody conjugates.

Summary

• C4 Therapeutics reported financial results for the first quarter ended March 31, 2026.
• The company advanced its cemsidomide program for multiple myeloma, initiating new clinical trials and planning further combination studies.
• A new collaboration agreement with Roche was established in April 2026, focusing on the discovery and development of degrader-antibody conjugates (DACs).
• C4 Therapeutics received a $20 million upfront payment from Roche in May 2026.
• The company decided not to advance CFT8919, an EGFR L858R degrader, into the next phase of clinical development outside of Greater China.
• Cash, cash equivalents, and marketable securities totaled $268.3 million as of March 31, 2026, with a projected cash runway to the end of 2028.
• Total revenue for Q1 2026 was $6.2 million, a decrease from $7.2 million in Q1 2025, attributed to the conclusion of a Merck collaboration.
• Net loss for Q1 2026 was $25.1 million, or $0.20 per share, an improvement from a net loss of $26.3 million, or $0.37 per share, in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong progress in clinical development and a significant partnership expansion, offset by a decrease in revenue and a strategic decision to halt a development program.

Positives

• Strong cash position of $268.3 million as of March 31, 2026, providing a cash runway to the end of 2028.
• Initiation of two new clinical trials for cemsidomide in multiple myeloma (Phase 2 MOMENTUM and Phase 1b combination with elranatamab).
• Expansion of partnership with Roche through a new collaboration agreement focused on degrader-antibody conjugates, including a $20 million upfront payment.
• Positive data from Phase 1 trial of cemsidomide showing differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity.
• Progress in advancing cemsidomide as a potential foundational therapy for multiple myeloma.
• Received a $2.0 million milestone from Biogen during the period ended March 31, 2026.

Negatives

• Total revenue decreased to $6.2 million in Q1 2026 from $7.2 million in Q1 2025, primarily due to the conclusion of a research collaboration with Merck.
• Decision to not advance CFT8919 into the next phase of clinical development outside of Greater China.
• Net loss of $25.1 million in Q1 2026, although improved from the prior year.

Risks

• Uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies.
• The risk that product candidates may not be successfully developed or commercialized.
• The risk that sufficient capital may not be available on acceptable terms or at the required times to fund future operations.
• Potential for drug resistance and the need for new therapeutic options in multiple myeloma.
• Competition in the multiple myeloma treatment landscape with emerging immune-directed approaches.

Future Outlook

The company expects its current cash, cash equivalents, and marketable securities to fund its operations to the end of 2028. Key upcoming milestones include presenting data from Phase 2 MOMENTUM and Phase 1b trials, initiating a Phase 3 trial for cemsidomide, and delivering development candidates to collaboration partners.

Management Comments

• "During the first quarter, we made strong progress advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for the treatment of multiple myeloma, highlighted by the initiation of two new clinical trials and plans to begin an additional combination trial next year."
• "We believe our clinical development path further supports the advancement of IKZF1/3 degradation - the only mechanism targeting a central transcriptional dependency in multiple myeloma -and will help position cemsidomide as a potentially foundational therapy for these patients with relapsed refractory disease."
• "In addition to these clinical advances, we also expanded our partnership with Roche through a new collaboration focused on degrader-antibody conjugates, broadening the reach of targeted protein degradation in cancer."
• "Supported by a strong balance sheet through key value inflection points, we remain focused on advancing our portfolio to deliver the next generation of targeted protein degrader medicines to patients."

Industry Context

StockSavvy.ai notes that C4 Therapeutics' focus on targeted protein degradation (TPD) aligns with a significant trend in biopharmaceutical innovation, particularly in oncology. The expansion of their collaboration with Roche into degrader-antibody conjugates (DACs) reflects the industry's exploration of novel therapeutic modalities to overcome resistance and target difficult-to-treat diseases.

Comparison to Industry Standards

• Cross-trial comparisons of Overall Response Rate (ORR) for cemsidomide in Phase 1 dose escalation show 36% ORR across all doses and 55% ORR at the highest dose level, which are presented alongside data for Mezigdomide and Iberdomide. These comparisons are noted as requiring caution due to the lack of head-to-head studies.
• The company's cash runway to the end of 2028 is a positive indicator, suggesting financial stability compared to many clinical-stage biopharmaceutical companies that often face funding challenges.
• The decision to halt development of CFT8919 outside of Greater China, based on evolving treatment landscape and capital priorities, is a strategic move common in the industry to focus resources on more promising candidates.

Stakeholder Impact

• Shareholders: The company's strong cash position and progress in clinical trials and partnerships are positive indicators for long-term value. The decision to halt CFT8919 development may be viewed as a prudent reallocation of resources.
• Employees: Continued investment in R&D and strategic collaborations suggest ongoing opportunities and stability within the company.
• Patients: Advancements in cemsidomide trials offer potential new treatment options for multiple myeloma patients, particularly those with relapsed/refractory disease.
• Partners (Roche, Biogen): The expanded collaboration with Roche and the milestone payment from Biogen highlight successful and ongoing partnerships.

Next Steps

• Initiate an additional Phase 1b trial evaluating cemsidomide in combination with approved multiple myeloma therapies in the first half of 2027.
• Provide an update on the dose escalation progress from the Phase 1b trial evaluating the combination of cemsidomide, dexamethasone, and elranatamab in 2H 2026.
• Deliver at least one development candidate to a collaboration partner and advance collaborations toward key milestones by year-end 2026.
• Complete enrollment for the Phase 2 MOMENTUM trial by the end of Q1 2027.
• Present initial ORR data from the Phase 2 MOMENTUM trial in 2H 2027.
• Present Phase 1b data from all cohorts (cemsidomide + elranatamab) in mid-2027.
• Initiate and enroll a Phase 3 trial of cemsidomide + BCMAxCD3 Bispecific.
• Potentially submit an NDA for cemsidomide.

Key Dates

Recommendation

The company shows promising clinical development and strategic partnerships, particularly with Roche, and maintains a strong cash position. However, revenue has declined, and a development program was deprioritized. While positive, these factors warrant a 'hold' recommendation pending further clinical data and revenue growth.

Keywords

C4 Therapeutics, Cemsidomide, Multiple Myeloma, Targeted Protein Degradation, Clinical Trials, Roche Collaboration, Biopharmaceutical, Oncology